Saldou N, Obernolte R, Huber A, Baecker P A, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C, Jarnagin K, Shelton E R
Roche Bioscience, Palo Alto, California 94304, USA.
Cell Signal. 1998 Jun;10(6):427-40. doi: 10.1016/s0898-6568(97)00169-1.
Four cyclic-nucleotide phosphodiesterase (PDE) genes belonging to the PDE4 family (PDE4A, 4B, 4C and 4D) have been identified. All four isogenes, including several deletions and alterations of the amino, carboxyl and central catalytic domains, were expressed in insect cells. Lysates were characterised for enzyme activity by using the Km for substrate and the EC50 for activation by the cofactor Mg2+. The catalytic domain alone appears to be sufficient for the normal enzymatic function of PDE4 proteins. Substrate affinity varied by less than 2-fold between catalytic-domain forms of the PDE4A, 4B and 4D isogenes and the long forms (PDE4A5, PDE4B1 and PDE4D3). The affinity for Mg2+ varied by less than 4-fold between long and catalytic-domain forms of PDE4A and 4B. The catalytic-domain form of PDE4D, however, had a 12-fold lower affinity for Mg2+ that was restored by including a portion of the amino-terminal domain, upstream conserved region-2 (UCR2). This result suggests that the Mg2+-binding site of PDE4D involves the UCR2 region. Inhibition of the PDE4 proteins by synthetic compounds is apparently affected differently by the domains. For PDE4B, the catalytic domain is sufficient for interactions with the inhibitors studied: IBMX, trequinsin, rolipram, TVX 2706, RP 73401 and RS-25344. For PDE4D the catalytic-domain form is less sensitive than the long form to inhibition by RS-25344, rolipram and TVX 2706, by 1463-, 11-and 12-fold, respectively. Addition of UCR2 to the catalytic-domain form of PDE4D restored all the lost sensitivities. The catalytic-domain form of PDE4A showed a reduced inhibitor affinity with RS-25344 and TVX 2706 by 77- and 90-fold, respectively. Both catalytic-domain and long forms of PDE4 isogenes interacted with equal affinity with the non-specific inhibitors IBMX and trequinsin, as well as the very potent PDE4-specific inhibitor RP 73401. Other potent and specific PDE4 inhibitors, such as rolipram, RS-25344 or TVX 2706, appear to utilize non-catalytic domain interactions with PDE4D and 4A to supplement those within the catalytic domains. These observations suggest a different relation between amino and catalytic domains in PDE4D relative to PDE4B. We therefore propose a model to illustrate these isogene-specific PDE4 domain interactions with substrate, inhibitors and the co-factor Mg2+. The model for PDE4D is also discussed in relation to changes in the activation curve for Mg2+ and sensitivity to RS-25344 that accompany phosphorylation of the long form by protein kinase A.
已鉴定出四个属于磷酸二酯酶4(PDE4)家族的环核苷酸磷酸二酯酶(PDE)基因(PDE4A、4B、4C和4D)。所有这四个同基因,包括氨基、羧基和中央催化结构域的若干缺失和改变,均在昆虫细胞中表达。通过使用底物的米氏常数(Km)和辅因子Mg2+激活的半数有效浓度(EC50)对裂解物的酶活性进行了表征。单独的催化结构域似乎足以实现PDE4蛋白的正常酶功能。PDE4A、4B和4D同基因的催化结构域形式与长形式(PDE4A5、PDE4B1和PDE4D3)之间的底物亲和力变化小于2倍。PDE4A和4B的长形式与催化结构域形式之间对Mg2+的亲和力变化小于4倍。然而,PDE4D的催化结构域形式对Mg2+的亲和力低12倍,通过包含氨基末端结构域的一部分,即上游保守区域2(UCR2)可恢复该亲和力。该结果表明PDE4D的Mg2+结合位点涉及UCR2区域。合成化合物对PDE4蛋白的抑制作用显然受不同结构域的影响不同。对于PDE4B,催化结构域足以与所研究的抑制剂相互作用:异丁基甲基黄嘌呤(IBMX)、曲喹辛、咯利普兰、TVX 2706、RP 73401和RS - 25344。对于PDE4D,催化结构域形式对RS - 25344、咯利普兰和TVX 2706抑制的敏感性分别比长形式低1463倍、11倍和12倍。将UCR2添加到PDE4D的催化结构域形式中可恢复所有丧失的敏感性。PDE4A的催化结构域形式与RS - 2534囷TVX 2706的抑制剂亲和力分别降低了77倍和90倍。PDE4同基因的催化结构域形式和长形式与非特异性抑制剂IBMX和曲喹辛以及非常有效的PDE4特异性抑制剂RP 73401以相同的亲和力相互作用。其他有效的和特异性的PDE4抑制剂,如咯利普兰、RS - 25344或TVX 2706,似乎利用与PDE4D和4A的非催化结构域相互作用来补充催化结构域内的相互作用。这些观察结果表明PDE4D中氨基结构域与催化结构域之间相对于PDE4B存在不同的关系。因此,我们提出一个模型来说明这些同基因特异性的PDE4结构域与底物、抑制剂和辅因子Mg2+的相互作用。还讨论了PDE4D的模型与蛋白激酶A对长形式磷酸化时Mg2+激活曲线变化和对RS - 25344敏感性的关系。